Streetbeat News

INNPF

InnoCan Pharma Corp

https://innocanpharma.com/

Industry

Pharmaceutical Preparation Manufacturing

Open

0.16

Mkt cap

45M

Volume

22K

High

0.16

P/E Ratio

-15.68

52-wk high

0.30

Low

0.16

Div yield

N/A

52-wk low

0.09

The article lists the cannabis stocks that gained and lost on August 11, 2023. Notable gainers include Australis Capital (OTC:AUSAF), StateHouse Hldgs (OTC:STHZF), and Hemp (OTC:HEMP). Significant losers include Chalice Brands (OTC:CHALF), Radient Technologies (OTC:RDDTF), and Maple Leaf Green World (OTC:MGWFF).

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 9:30 pm

Innocan Pharma Corporation has closed a non-brokered private placement offering of 8.4 million units at a price of CA$0.23 per unit, raising CA$1.9 million ($1.4 million). Each unit consists of one common share, one-half of one class A common share purchase warrant, and one-half of one class B common share purchase warrant. The proceeds will be used for working capital and general corporate purposes.

Portfolio Pulse from Vuk Zdinjak

August 04, 2023 | 3:09 pm

Innocan Pharma Corporation plans to complete a non-brokered private placement of up to 17.22 million units at a price of CA$0.23 per unit, raising up to CA$3.96 million ($3 million). The offering is expected to close on or around July 20, 2023. The proceeds will be used for working capital and general corporate purposes. The securities will be subject to a hold period of four months and one day from the date of issuance.

Portfolio Pulse from Vuk Zdinjak

July 25, 2023 | 11:46 am

On July 21, 2023, several cannabis stocks experienced significant price movements. Notable gainers included Craftport Cannabis (OTC:BHHKF), Choom Holdings (OTC:CHOOF), and Tetra Bio Pharma (OTC:TBPMF), with shares closing up 580.00%, 125.00%, and 121.31% respectively. On the other hand, Hemp (OTC:HEMP), Avenir Wellness Solutions (OTC:CURR), and 1606 (OTC:CBDW) were among the biggest losers, with shares closing down 50.00%, 27.57%, and 18.75% respectively.

Portfolio Pulse from Benzinga Insights

July 21, 2023 | 9:30 pm

Innocan Pharma Corporation reported Q1 2023 revenue of $1.6 million, a 500% increase compared to Q1 2022, mainly due to increased sales from its subsidiary, B.I. Sky Global Ltd. Gross profit was $1.4 million, and gross profit margin was 87.8%. The company's cash balance stood at $4.1 million as of March 31, 2023.

Portfolio Pulse from Vuk Zdinjak

June 01, 2023 | 1:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.